KUP101
Cutaneous Squamous Cell Carcinoma (cSCC)
Key Facts
About Kupando
Kupando is a private, preclinical-stage biotech pioneering a novel therapeutic approach using dual TLR4/7 agonists to stimulate innate and trained immunity. Its lead asset, KUP101, is being developed for tissue-agnostic solid tumors and AMR infections, with CTA-enabling studies underway for cutaneous squamous cell carcinoma. The company's platform offers a differentiated, host-directed mechanism with potential as monotherapy or in combination, backed by preclinical proof-of-concept and non-dilutive funding from the German Federal Ministry of Education and Research.
View full company profileAbout Kupando
Kupando is a private, preclinical-stage biotech pioneering a novel therapeutic approach using dual TLR4/7 agonists to stimulate innate and trained immunity. Its lead asset, KUP101, is being developed for tissue-agnostic solid tumors and AMR infections, with CTA-enabling studies underway for cutaneous squamous cell carcinoma. The company's platform offers a differentiated, host-directed mechanism with potential as monotherapy or in combination, backed by preclinical proof-of-concept and non-dilutive funding from the German Federal Ministry of Education and Research.
View full company profileAbout Kupando
Kupando is a private, preclinical-stage biotech pioneering a novel therapeutic approach using dual TLR4/7 agonists to stimulate innate and trained immunity. Its lead asset, KUP101, is being developed for tissue-agnostic solid tumors and AMR infections, with CTA-enabling studies underway for cutaneous squamous cell carcinoma. The company's platform offers a differentiated, host-directed mechanism with potential as monotherapy or in combination, backed by preclinical proof-of-concept and non-dilutive funding from the German Federal Ministry of Education and Research.
View full company profileAbout Kupando
Kupando is a private, preclinical-stage biotech pioneering a novel therapeutic approach using dual TLR4/7 agonists to stimulate innate and trained immunity. Its lead asset, KUP101, is being developed for tissue-agnostic solid tumors and AMR infections, with CTA-enabling studies underway for cutaneous squamous cell carcinoma. The company's platform offers a differentiated, host-directed mechanism with potential as monotherapy or in combination, backed by preclinical proof-of-concept and non-dilutive funding from the German Federal Ministry of Education and Research.
View full company profileTherapeutic Areas
Other Cutaneous Squamous Cell Carcinoma (cSCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Prognostic Test | AMLo Biosciences | Pre-clinical |
| UNLOXCYT™ (cosibelimab-ipdl) | Fortress Biotech | Marketed |